The Protein Brewery Closes 18 Million Euro Series B Extension Ahead of European Launch

The Protein Brewery, a company specializing in biomass fermentation producing whole-food mycelium-based protein, announced an extension of its Series B funding round by 18 million euros, led by incoming investor ABN AMRO Sustainable Impact Fund.

The round was joined by existing investors Invest-NL, Novo Holdings, Madeli, and the Brabant Development Agency.

The investment marks an acceleration in the company’s growth, which will help to scale up production capacity, expand commercially across Europe following EU novel food authorization, and deepen the science behind its flagship ingredient, Fermotein. Total funding to date has reached 70 million euros.

The funding will:

• Expand production capacity to more than 2,000 metric tons through capital investment and growing operations at the Mijkenbroek, Netherlands facility;
• Drive sales in Europe after summer 2026, with a focus on active nutrition ready-to-mix powders and bars, functional foods, and beverages;
• Advance clinical and scientific research on the topic of longevity;
• And pursue regulatory approvals in new markets, including Canada, Australia, New Zealand, and India.

“Building a completely new ingredient category takes patience and investment in the right activities, at the right time,” said Thijs Bosch, CEO. “With this additional funding, we move from proving that whole-food mycelium is a desirable ingredient to delivering it at the scale that brands and manufacturers need. Fermotein meets the challenge of feeding a growing and aging population with fewer environmental resources. ABN AMRO Sustainable Impact Fund is the right partner because they understand that high-quality nutrition and sustainability go hand in hand.”

“The Protein Brewery has successfully translated strong scientific foundations into a robust industrial-scale production process and a growing commercial business, exactly the profile we look for in companies that can deliver measurable environmental impact at scale,” said Ugur Yuksel, investment manager, ABN AMRO Sustainable Impact Fund. “We are pleased to support its next phase of growth.”

Over the past year, the protein brewery secured European Commission authorization, becoming the first novel EU-grown mycelium ingredient cleared under the EU Novel Food Regulation. It sold out its 2026 capacity to customers in the U.S. and built a pipeline in the EU and UK with initial customers in active nutrition. The company’s full supply chain has been established, from fermentation to finished product. The company won the “Most Innovative Sustainable Solution” at the Vitafoods Europe startup challenge.